As the global burden of Parkinson’s disease continues to grow, especially with aging populations, there is a pressing need for advanced therapies that improve motor control and extend the effectiveness of standard treatments. Among the latest breakthroughs is Opicapone, a third-generation COMT inhibitor that is reshaping the way we manage Parkinson’s symptoms.
What is Opicapone and How Does It Work?
Opicapone is an innovative Catechol-O-methyltransferase (COMT) inhibitor used as an adjunct to levodopa/carbidopa therapy in adult patients with Parkinson’s disease who experience end-of-dose motor fluctuations. Unlike earlier COMT inhibitors, Opicapone is potent, reversible, and acts peripherally, which means it does not cross the blood-brain barrier and reduces potential side effects.
By inhibiting COMT, Opicapone prevents the breakdown of levodopa in the periphery, prolonging its half-life and increasing its availability to the brain. This leads to smoother and more sustained symptom control for patients battling motor fluctuations—a significant challenge in long-term Parkinson’s management.
Why Choose Suanfarma’s Opicapone?
At Suanfarma, we’re dedicated to supporting pharmaceutical innovation with APIs that meet the highest standards of quality and regulatory compliance. Here’s why our Opicapone is an ideal choice for your next formulation:
🔹 High Purity & Low Impurities – Our Opicapone features a purity of over 98% with total impurities around 0.1%, ensuring optimal performance and safety in final formulations.
🔹 Long-Acting Oral Therapy – Designed for once-daily administration, Opicapone offers 24-hour action, enhancing patient adherence and convenience.
🔹 Reliable European Manufacturing – Produced in Europe, our Opicapone benefits from stringent manufacturing practices and a strong global commercial team ready to support your market needs.
🔹 Industrial Availability by Q1 2026 – Secure your supply ahead of time. Opicapone will be available for large-scale industrial production starting in Q1 2026.
🔹 Sustainable and Cost-Effective – Our production strategy combines sustainability and market competitiveness, ensuring you receive high-value APIs at accessible prices.
With 4–5 million potential treatment candidates globally and a projected CAGR of over 1.8% (2023–2033), the market for Parkinson’s therapies continues to grow steadily. Opicapone stands out as a reliable and advanced option for pharmaceutical companies looking to expand their anti-Parkinson portfolios.
Our GMP-certified facilities and ongoing flow technology developments ensure that every batch of Opicapone meets rigorous standards of safety, consistency, and performance.
